My view is it will only increase competition for the good drugs in buyout. The ones that have greatest revenue growth potential.
Greater competition amongst big pharma. Imagine Merck, Pfizer, Novaritis, GSK, etc, etc all getting interested.
Have a look at the number of trials for Keytruda ... over 1,400.
https://clinicaltrials.gov/ct2/resu...uda&cntry=&state=&city=&dist=
My view is it will only increase competition for the good drugs...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |